<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ma X</submitter><funding>Pengcheng Yingcai Medical Youth Reserve Talent Training Project</funding><funding>Applied Basic Research of Yunnan Science &amp;amp; Technology Agency</funding><funding>National Natural Science Foundation of China</funding><funding>Natural Science Foundation of Jiangsu Province</funding><pagination>2493556</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12010658</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>30(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Pulmonary metastases in osteosarcoma (OS) are associated with a poor prognosis. Rotenone has shown anti-cancer activity. However, its effects on metastasis and the underlying mechanisms remain unknown. This study investigated the potential use of Rotenone for OS treatment.&lt;h4>Methods&lt;/h4>The effect of Rotenone and ROS/Ca&lt;sup>2+&lt;/sup>/AMPK/ZO-2 pathway on metastasis and EMT was evaluated by Western blot, Transwell and Wound healing. Flow cytometer was employed to measure the intracellular Ros and Ca&lt;sup>2+&lt;/sup> levels. The subcellular location of ZO-2 was detected by IF, interaction between AMPK and ZO-2 were examined by Co-IP. Then, subcutaneous tumor and metastasis models were used to evaluate the function of Rotenone in OS metastasis.&lt;h4>Results&lt;/h4>Rotenone-induced R</pubmed_abstract><journal>Redox report : communications in free radical research</journal><pubmed_title>Rotenone inhibited osteosarcoma metastasis by modulating ZO-2 expression and location via the ROS/Ca&amp;lt;sup&amp;gt;2+&amp;lt;/sup&amp;gt;/AMPK pathway.</pubmed_title><pmcid>PMC12010658</pmcid><funding_grant_id>BK20220235</funding_grant_id><funding_grant_id>XWRCHT20220028</funding_grant_id><funding_grant_id>82203396</funding_grant_id><funding_grant_id>BK20231164</funding_grant_id><funding_grant_id>202201AY070001[-152]</funding_grant_id><pubmed_authors>Jiang K</pubmed_authors><pubmed_authors>Yang Z</pubmed_authors><pubmed_authors>Li Z</pubmed_authors><pubmed_authors>Zhu Z</pubmed_authors><pubmed_authors>Ma X</pubmed_authors><pubmed_authors>Ma H</pubmed_authors><pubmed_authors>Wang W</pubmed_authors><pubmed_authors>Yunqing W</pubmed_authors><pubmed_authors>Chen B</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Dong S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Rotenone inhibited osteosarcoma metastasis by modulating ZO-2 expression and location via the ROS/Ca&amp;lt;sup&amp;gt;2+&amp;lt;/sup&amp;gt;/AMPK pathway.</name><description>&lt;h4>Background&lt;/h4>Pulmonary metastases in osteosarcoma (OS) are associated with a poor prognosis. Rotenone has shown anti-cancer activity. However, its effects on metastasis and the underlying mechanisms remain unknown. This study investigated the potential use of Rotenone for OS treatment.&lt;h4>Methods&lt;/h4>The effect of Rotenone and ROS/Ca&lt;sup>2+&lt;/sup>/AMPK/ZO-2 pathway on metastasis and EMT was evaluated by Western blot, Transwell and Wound healing. Flow cytometer was employed to measure the intracellular Ros and Ca&lt;sup>2+&lt;/sup> levels. The subcellular location of ZO-2 was detected by IF, interaction between AMPK and ZO-2 were examined by Co-IP. Then, subcutaneous tumor and metastasis models were used to evaluate the function of Rotenone in OS metastasis.&lt;h4>Results&lt;/h4>Rotenone-induced R</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2025-07-01T03:04:54.776Z</modification><creation>2025-07-01T03:04:54.776Z</creation></dates><accession>S-EPMC12010658</accession><cross_references><pubmed>40247635</pubmed><doi>10.1080/13510002.2025.2493556</doi></cross_references></HashMap>